Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abiraterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 16/20 | 1.00 |
| ▸ | AR known ✓ | P10275 | 1/20 | 0.71 |
| ▸ | CYP21A2 | P08686 | 6/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abiraterone SCHEMBL16383633 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL17474701 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL61108 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL20459184 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL23924960 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL25074918 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL13272100 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL19724576 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL22414103 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL15700283 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282872-A1 | PREPARATION METHOD FOR AND APPLICATION OF NOVEL INJECTION ABIRATERONE DERIVATIVE | Tianjin Hairunjiahe Innovative Pharmaceutical Research Limited Liability Company (CN) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023131310-A1 | STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-13 | — | — | WO | disclosed |
| EP-3514147-B1 | STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIV MARYLAND (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3392261-B1 | STEROIDAL COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-04-14 | — | — | US | disclosed |
| US-10265329-B2 | Altering steroid metabolism for treatment of steroid-dependent disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190040098-A1 | STEROIDAL COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| EP-3027638-B1 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND ABIRATERONE ACETATE | IND CHIMICA SRL (IT) | 2017-12-27 | — | — | EP | disclosed |
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-7875599-B2 | 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme ) | UNIVERSITY OF MARYLAND (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875599-B2 | 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme ) | UNIVERSITY OF MARYLAND (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1853619-B1 | 3-BETA-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE FOR USE IN THE TREATMENT OF A PROSTATE DISEASE | UNIV MARYLAND (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010091303-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091306-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-06-03 | — | — | US | disclosed |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-06-03 | — | — | US | disclosed |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265329-B2 | Altering steroid metabolism for treatment of steroid-dependent disease | CYP17A1, CYP21A2, HSD17B1 | CYP17A1 1/4885AR 61/4885CYP21A2 2/4885 |
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP11B1, HSD17B7, CYP17A1 | CYP17A1 3/4885AR 18/4885CYP21A2 6/4885 |
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP17A1, HSD17B1, HSD17B7 | CYP17A1 1/4885AR 12/4885CYP21A2 4/4885 |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, CYP21A2, HSD17B1 | CYP17A1 1/4885AR 14/4885CYP21A2 2/4885 |
| US-20190040098-A1 | STEROIDAL COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | CYP21A2, CYP17A1, HSD17B7 | CYP17A1 2/4885AR 55/4885CYP21A2 1/4885 |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | AR, NR5A1, BRCA1 | CYP17A1 11/4885AR 1/4885CYP21A2 31/4885 |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, CYP21A2 | CYP17A1 1/4885AR 12/4885CYP21A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.